From the publishers of JADPRO

DLBCL Resource Center


Assessment of salvage regimens post CAR-T cell therapy for patients with diffuse large B-cell lymphoma

According to data from a retrospective analysis of DLBCL patients with progressive disease after receiving anti-CD19 CAR T-cell therapy, those who responded to CAR19 therapy have significantly better median overall survival with salvage therapy (i.e., lenalidomide, Bruton tyrosine kinase inhibitor, checkpoint inhibitor, chemo-immunotherapy, allogeneic transplant, and other) compared with CAR19 non-responders (not reached vs. 10.9 months, respectively; P = .0187).

Transplantation and Cellular Therapy
News & Literature Highlights

Medpage Today

New antibody-drug conjugate OK'd in DLBCL

Journal of Clinical Oncology

Monitoring of circulating tumor DNA improves early relapse detection after axicabtagene ciloleucel infusion in large B-cell lymphoma: results of a prospective multi-institutional trial

American Journal of Hematology

2021 update on diffuse large B cell lymphoma: a review of current data and potential applications on risk stratification and management


Treatment resistance in diffuse large B-cell lymphoma

Blood Advances

Impact of rituximab biosimilars on overall survival in diffuse large B-cell lymphoma: a Dutch population-based study


Genomic complexity is associated with epigenetic regulator mutations and poor prognosis in diffuse large B-cell lymphoma


Male and female fertility: Prevention and monitoring Hodgkin’ lymphoma and diffuse large B-cell lymphoma adult survivors. A systematic review by the Fondazione Italiana Linfomi

Journal of Clinical Oncology

Simplified geriatric assessment in older patients with diffuse large B-cell lymphoma: the prospective Elderly Project of the Fondazione Italiana Linfomi

British Journal of Haematology

Age is the most important predictor of survival in diffuse large B-cell lymphoma patients achieving event-free survival at 24 months: a Swedish population-based study

Journal of Clinical Oncology

Glofitamab, a novel, bivalent CD20-targeting T-cell–engaging bispecific antibody, induces durable complete remissions in relapsed or refractory B-cell lymphoma: a phase I trial